A multicenter, randomized controlled trial assessing Ipragliflozin ameliorated overweight and pathological liver fibrosis in diabetic patients with nonalcoholic fatty liver disease
Latest Information Update: 16 Oct 2020
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 29 Aug 2020 Results (n=46) assessing SGLT2 effect on pathogenesis of NAFLD including pathological findings, presented at The International Liver Congress 2020.
- 23 Jul 2020 New trial record
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association